Literature DB >> 23587491

Recurrent periprosthetic joint infection: persistent or new infection?

Benjamin Zmistowski1, Matthew W Tetreault, Pouya Alijanipour, Antonia F Chen, Craig J Della Valle, Javad Parvizi.   

Abstract

It is unclear if recurrent periprosthetic joint infection (PJI) is a result of failed pathogen eradication. This study addresses this issue. We identified 92 patients from three institutions who failed two-stage exchange. Cultured organisms at each stage of treatment were compared to determine whether these were persistent or new infections. Only twenty-nine of the 92 patients (31.5%) had identical organisms at treatment failure. Of the failures associated with Staphylococcus as the original infecting organism, 37% (25 of 67) failed due to the same organism compared to only 16% (four of 25) caused by other organisms. Positive cultures at reimplantation and poor health status were associated with higher rates of recurrent infection due to new organisms. Successful management of PJI with a two-stage exchange must stress minimization of comorbid risk factors that may contribute to the low success rate of PJI treatment and recurrence of infection.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  periprosthetic joint infection; persistent infection; recurrent infection

Mesh:

Year:  2013        PMID: 23587491     DOI: 10.1016/j.arth.2013.02.021

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  33 in total

1.  Preoperative aspiration culture for preoperative diagnosis of infection in total hip or knee arthroplasty.

Authors:  Xinhua Qu; Zanjing Zhai; Chuanlong Wu; Fangchun Jin; Haowei Li; Lei Wang; Guangwang Liu; Xuqiang Liu; Wengang Wang; Huiwu Li; Xiaoyu Zhang; Zhenan Zhu; Kerong Dai
Journal:  J Clin Microbiol       Date:  2013-08-14       Impact factor: 5.948

2.  Infection post-total knee replacement: current concepts.

Authors:  Pouya Alijanipour; Javad Parvizi
Journal:  Curr Rev Musculoskelet Med       Date:  2014-06

3.  CORR Insights®: Sonication of antibiotic spacers predicts failure during two-stage revision for prosthetic knee and hip infections.

Authors:  Charalampos G Zalavras
Journal:  Clin Orthop Relat Res       Date:  2014-04-29       Impact factor: 4.176

4.  CORR Insights(®): Are Frozen Sections and MSIS Criteria Reliable at the Time of Reimplantation of Two-stage Revision Arthroplasty?

Authors:  Craig J Della Valle
Journal:  Clin Orthop Relat Res       Date:  2016-01-14       Impact factor: 4.176

5.  Positive Alpha-defensin at Reimplantation of a Two-stage Revision Arthroplasty Is Not Associated with Infection at 1 Year.

Authors:  Linsen T Samuel; Assem A Sultan; Matthew Kheir; Jesus Villa; Preetesh Patel; Javad Parvizi; Carlos A Higuera
Journal:  Clin Orthop Relat Res       Date:  2019-07       Impact factor: 4.176

6.  Late Reinfection May Recur More Than 5 Years After Reimplantation of THA and TKA: Analysis of Pathogen Factors.

Authors:  Kevin L Garvin; Ryan E Miller; Todd M Gilbert; Anthony M White; Elizabeth R Lyden
Journal:  Clin Orthop Relat Res       Date:  2018-02       Impact factor: 4.176

7.  Sonication Culture of Antimicrobial Agent-Containing Cement Spacers Removed during Staged Revisions for Arthroplasty Infection.

Authors:  Eric Gomez-Urena; Rafael J Sierra; Kerryl E Greenwood-Quiantance; Melissa J Karau; James M Steckelberg; Robin Patel
Journal:  J Clin Microbiol       Date:  2019-01-30       Impact factor: 5.948

8.  Synovial Alpha-defensin at Reimplantation in Two-stage Revision Arthroplasty to Rule Out Persistent Infection.

Authors:  Charlotte Bielefeld; Harald Engler; Marcus JÄger; Alexander Wegner; Dennis Wassenaar; Andre Busch
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

Review 9.  Patient-related medical risk factors for periprosthetic joint infection of the hip and knee.

Authors:  Aleeson Eka; Antonia F Chen
Journal:  Ann Transl Med       Date:  2015-09

Review 10.  Prosthetic joint infection.

Authors:  Aaron J Tande; Robin Patel
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.